GeneDx Holdings Launches ultraRapid Whole Genome Sequencing for Neonatal Care Enhancement

GeneDx Launches ultraRapid Whole Genome Sequencing for Neonatal Care

GeneDx Holdings, a leader in genomic healthcare solutions, introduces its ultraRapid Whole Genome Sequencing service aimed at neonatal and pediatric patients in Neonatal Intensive Care Units (NICUs) and Pediatric Intensive Care Units (PICUs). This innovative service promises to deliver comprehensive genomic insights within just two days, significantly enhancing the speed of diagnosis for critically ill infants. The expedited testing is designed to address the urgent need for timely genetic diagnosis, which can drastically impact clinical management decisions. By providing actionable genetic information quickly, GeneDx aims to reduce the lengthy NICU stays that can extend by 15 to 20 days for infants lacking a genetic diagnosis.

Genetic disorders are a leading cause of infant mortality, and the ability to secure a genetic diagnosis can influence clinical decisions for over 60% of infants in critical care. This rapid response could not only improve patient outcomes but also alleviate healthcare costs, potentially saving upwards of $15,000 per child. According to Paul Kruszka, MD, FACMG, Chief Medical Officer at GeneDx, the ultraRapid genome service is a crucial tool in overcoming the diagnostic challenges faced by families with critically ill infants. Despite the prevalence of genetic disorders—affecting up to 25% of NICU patients—less than 5% currently undergo genetic testing, highlighting a significant gap that GeneDx seeks to fill with its new offering.

The ultraRapid service is accessible through the GeneDx portal and is integrated with Epic Aura, ensuring seamless access for health systems and enhancing the overall delivery of care. Leveraging advanced technology and the company’s extensive experience in sequencing—having processed over 750,000 exomes and genomes—GeneDx is well-positioned to optimize lab processes for efficient sequencing, analysis, and interpretation. This initiative is part of GeneDx's broader commitment to providing a robust menu of genomics tests, including exome and rapid genome tests, which are designed to facilitate personalized medical care through accurate genetic diagnoses. The ultraRapid Genome service is set for ordering starting in March, further solidifying GeneDx's dedication to improving access to crucial genetic testing for patients in need.

In addition to the ultraRapid Whole Genome Sequencing, GeneDx continues to enhance its genomic testing capabilities, striving to address the pressing needs of healthcare providers and patients alike. The company's focus on improving access to genetic testing reflects its commitment to transforming healthcare through innovative genomic solutions. As the landscape of personalized medicine evolves, GeneDx remains at the forefront, offering tools that can significantly change the management and outcomes of critically ill infants.